Sanofi (SNY) reported revenues of ~8.7 billion euros in 4Q17, a decline of ~2.0% in revenues compared to ~8.9 billion euros in 4Q16. The decline in revenues was driven by an ~6.1% negative impact of foreign exchange, substantially offset by 4.1% growth in revenues at constant exchange rates.
Sanofi reported earnings per share (or EPS) of 1.06 euros in 4Q17. The chart below compares Sanofi’s revenues and EPS trend since 1Q16.
Forward PE multiple
PE (price-to-earnings) multiples are widely available and represent what one share can buy for an equity investor. On February 26, 2018, Sanofi was trading at a forward PE multiple of ~12.0x compared with the industry average of 13.4x.
Forward EV-to-EBITDA multiple
On a capital structure–neutral basis, Sanofi was trading at a forward EV-to-EBITDA[1. enterprise value to earnings before interest, tax, depreciation, and amortization] multiple of 8.5x on February 26, 2018, which is lower than the industry average of ~10.8x.